Blister package for pharmaceutical cartridges
A blister packaging for a pharmaceutical cartridge or capsule and methods of forming same are disclosed.
1. A package comprising:
a blistered base sheet including two or more horizontal rows of interconnected cavities wherein the two or more horizontal rows are situated vertically and at the same orientation, wherein each interconnected cavity includes two or more cavities wherein each of the cavities includes a cartridge that includes an injection molded cartridge lid and an injection molded cartridge container that is movable relative to the injection molded cartridge lid, wherein each of the cavities includes a dome structure holding the injection molded cartridge container and a shelf holding and touching the injection molded cartridge lid, and
wherein the one or more cartridges include a pharmaceutical formulation.
2. The package of claim 1 , wherein the pharmaceutical formulation comprises an active ingredient and a diketopiperazine.
3. The package of claim 2 , wherein the active ingredient selected from the group consisting of insulin, glucagon like peptide 1, glucagon, oxytocin, oxyntomodulin, peptide YY, sumatriptan, a peptidyl peptidase IV inhibitor, parathyroid hormone, a neurotransmitter agonist, a neurotransmitter antagonist molecule, deoxyribonuclease I, active fragments thereof, analogs thereof, or a combination thereof.
4. The package of claim 2 , wherein the diketopiperazine is bis-3,6-(N-fumaryl-4-aminobutyl)-2,5-diketo-diketopiperazine.
5. The package of claim 2 , wherein the diketopiperazine is
6. The package of claim 1 , wherein the injection molded cartridge lid extends over the injection molded cartridge container.
7. The package of claim 2 , wherein the active ingredient is a peptide, protein, a small molecule or a nucleic acid.
8. The package of claim 2 , wherein the active ingredient is a neurotransmitter agonist or a neurotransmitter antagonist molecule.
9. The package of claim 2 , wherein the active ingredient is insulin.
10. The package of claim 2 , wherein the active ingredient is glucagon like peptide 1.
11. The package of claim 2 , wherein the active ingredient is glucagon.
12. The package of claim 2 , wherein the active ingredient is at least one of oxytocin, oxyntomodulin, and peptide YY.
13. The package of claim 12 , wherein the active ingredient is oxytocin.
14. The package of claim 12 , wherein the active ingredient is oxyntomodulin.
15. The package of claim 12 , wherein the active ingredient is peptide YY.
16. The package of claim 1 , wherein the blistered base sheet comprises at least three layers selected from polyvinyl chloride and polychlorotrifluoroethylene.
17. The package of claim 16 , wherein the polychlorotrifluoroethylene layer forms the middle layer of the blistered base sheet having a thickness of about 230 μm to about 720 μm in thickness.
18. The package of claim 1 , further comprising a lid.
19. The package of claim 18 , wherein the lid comprises a foil comprising one or more layers selected from aluminum, plastic polymer or co-polymer.
20. The package of claim 18 , wherein the lid has a thickness of about 10 μm to 75 μm or a thickness greater than 100 μm.
21. The package of claim 1 , wherein the injection molded cartridge container is locked to the injection molded cartridge lid.
22. The package of claim 1 , wherein the pharmaceutical formulation is a dry powder.
23. The package of claim 1 , wherein the injection molded cartridge container is movable translationally relative to the injection molded cartridge lid.
24. The package of claim 1 further including a perforation between each of the two or more rows of interconnected cavities.